Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Journal of Alzheimer s Disease

Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CJChen JiangQJQI Jiang-ningHZHongfeng Zou

Discussion

Loading...

Member takes

Overview

Comprehensive analysis reveals specific antidiabetic therapies may slow cognitive decline in patients with T2D and AD, suggesting important clinical implications.

Key Points

  • Combination therapies with metformin and sulfonylureas significantly slow cognitive decline in Alzheimer's patients.
  • Analysis included 964 patients with both Alzheimer's disease and type 2 diabetes, monitored over a 17-year span.
  • Generalized linear mixed modeling was used to assess cognitive decline across different antidiabetic treatments.
  • Findings indicate critical insights for treating cognitive decline in patients affected by both AD and T2DM.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/68af5f13ad7bf08b1eae1d98https://doi.org/10.1177/13872877251365662
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<b>MatchIt</b>: Nonparametric Preprocessing for Parametric Causal Inference2011 · 4,496 citations
  2. 2Antidiabetic Drugs in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review2020 · 56 citations
  3. 3The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study2021 · 16 citations
  4. 4Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study2010 · 353 citations
  5. 5Increased Risk of Type 2 Diabetes in Alzheimer Disease2004 · 962 citations